Major histocompatibility complex

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Major histocompatibility complex, CPI, Cell, Entrepreneurship, Oncology, Immunotherapy, DLL4, Patient, Neoplasm, Data, Tumor microenvironment, VEGF, Checkpoint, Doctor of Philosophy, MD, Natural killer T cell, News, AACR, MHC, Research and development, Therapy, MHC-I, Antibody, Immune system, PD-L1, San Diego Convention Center, NK, PD-1, Vaccine

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points: 
  • Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
  • The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
  • Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
  • A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.

CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy

Retrieved on: 
Monday, January 29, 2024
Patient, Prostate cancer, Radiation, Partnership, Consultant, Society, University of Chicago, DFS, University, Principal investigator, Risk, Immunotherapy, Recurrence, IND, Food, ADT, MHC, FDA, Investigational New Drug, CDMO, CGMP, Clinical trial, Phase, Prostatectomy, Major histocompatibility complex, Pharmaceutical industry

FK-PC101 is CellVax's novel personalized cancer immunotherapy intended to treat prostate cancer patients who have a high risk of recurrence after prostatectomy.

Key Points: 
  • FK-PC101 is CellVax's novel personalized cancer immunotherapy intended to treat prostate cancer patients who have a high risk of recurrence after prostatectomy.
  • It consists of patient's own tumor cells which are collected during surgery, then modified in the laboratory.
  • Fernando Kreutz, CEO at CellVax, stated, "We are thrilled to receive FDA clearance of our FK-PC101 IND.
  • The trial, CELLVX-230, is a randomized, multicenter, open-label study of irradiated autologous cellular vaccine in men with high-risk prostate cancer post-radical prostatectomy.

Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer

Retrieved on: 
Tuesday, June 28, 2022
Transfer, Patient, Research, National Institute, Immunosuppression, Cancer, Company, Cytokine, NSCLC, Mab, Immunoglobulin G, SVP, IND, Communication, Doctor of Philosophy, Drug development, Nature, Therapy, VISTA, Fred Hutchinson Cancer Research Center, Securities Act of 1933, Prospectus, Neck, University of Rennes 1, Lung cancer, SEC, Immunotherapy, Associate, Twitter, United States Secretary of Commerce, LinkedIn, CD24, Catholic University of Toulouse, Technology, CD27, Neutralizing antibody, IRT, Lung, Multimedia, B-cell lymphoma, Head, Sale, U.S. Securities and Exchange Commission, Form, Major histocompatibility complex, University, Antibody, Technology transfer, Human, Tumor microenvironment, Program, Pharmaceutical industry, Vaccine, Security (finance), Kineta, Yuman–Cochimí languages, Shareholder, Facebook

SEATTLE, June 28, 2022 /PRNewswire/ -- Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer of the Company.

Key Points: 
  • SEATTLE, June 28, 2022 /PRNewswire/ -- Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer of the Company.
  • As Chief Scientific Officer, Dr. Guillaudeux will lead Kineta's R&D team and oversee all of Kineta's innovative drug programs from discovery through clinical development.
  • "Dr. Guillaudeux is a highly regarded immunologist and an exceptional leader, and we are pleased to recognize his contributions to the Company with his promotion to Chief Scientific Officer," said Shawn Iadonato, PhD, Chief Executive Officer of Kineta.
  • For more information on Kineta please visit www.kinetabio.com , and follow Kineta on Twitter , LinkedIn and Facebook .

Why Do Some Neurons Degenerate and Die in Alzheimer's Disease, but Not Others?

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Biology, Alzheimer's disease, Apolipoprotein E, Apolipoproteins, Neuron, APOE, Memory, Major histocompatibility complex, Brain

b'SAN FRANCISCO, May 6, 2021 /PRNewswire/ -- In the brain of a person with Alzheimer\'s disease, neurons degenerate and die, slowly eliminating memories and cognitive skills.

Key Points: 
  • b'SAN FRANCISCO, May 6, 2021 /PRNewswire/ -- In the brain of a person with Alzheimer\'s disease, neurons degenerate and die, slowly eliminating memories and cognitive skills.
  • They found that, in both mouse and human neurons, high levels of apoE turned on genes in the major histocompatibility complex class-I (MHC-I).
  • "You don\'t want to keep damaged neurons around because they could malfunction and cause problems.
  • The study shows that neurons carrying the form of apoE associated with increased risk of Alzheimer\'s disease, apoE4, are particularly susceptible to these stressors.

SQZ Biotech Expands Cell Therapy Partnership with Roche to Develop Antigen Presenting Cells for Immune-Oncology

Retrieved on: 
Monday, October 15, 2018
Medicine, Immune system, Immunology, Biology, Antigen presenting cells, Cancer treatments, Virotherapy, Cancer immunotherapy, Immunotherapy, Major histocompatibility complex, Antigen

The expanded partnership furthers the synergistic combination of SQZ's innovation and expertise in cell therapy with Roche's cancer immunotherapy expertise.

Key Points: 
  • The expanded partnership furthers the synergistic combination of SQZ's innovation and expertise in cell therapy with Roche's cancer immunotherapy expertise.
  • Under the terms, SQZ and Roche will jointly develop and commercialize certain products based on antigen presenting cells (APCs) created by the SQZ platform for the treatment of oncology indications.
  • Antigen presenting cells (APCs), are cells that present antigen on their surface through major histocompatibility complexes (MHCs).
  • SQZ Biotechnologies is a Massachusetts-based, privately held company developing cellular therapies for multiple therapeutic areas using their proprietary cell therapy platform.